Spots Global Cancer Trial Database for confirmed
Every month we try and update this database with for confirmed cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | NCT01189929 | Pancreatic Canc... | Demcizumab Abraxane® Gemcitabine | 21 Years - | Mereo BioPharma | |
A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors | NCT00744562 | Solid Tumors | OMP-21M18 | 21 Years - | Mereo BioPharma | |
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer | NCT02259582 | Nonsquamous Non... | Pemetrexed Carboplatin demcizumab | 21 Years - | Mereo BioPharma | |
A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer | NCT01189968 | Non Small Cell ... | Demcizumab | 21 Years - | Mereo BioPharma | |
A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer | NCT01189942 | Colorectal Canc... | OMP-21M18 | 21 Years - | Mereo BioPharma | |
A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | NCT01189929 | Pancreatic Canc... | Demcizumab Abraxane® Gemcitabine | 21 Years - | Mereo BioPharma |